|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al Spanish Lung Cancer Group: Screening for epidermal growth
factor receptor mutations in lung cancer. N Engl J Med.
361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L,
Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, et al: Epidermal growth
factor receptor mutations and their correlation with gefitinib
therapy in patients with non-small cell lung cancer: A
meta-analysis based on updated individual patient data from six
medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small cell lung cancer: Role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene. 28(Suppl 1):
S24–S31. 2009. View Article : Google Scholar
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al North-East Japan Study Group: Gefitinib or chemotherapy for
non-small cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin Y, Wang X and Jin H: EGFR-TKI
resistance in NSCLC patients: Mechanisms and strategies. Am J
Cancer Res. 4:411–435. 2014.PubMed/NCBI
|
|
7
|
Kosaka T, Yatabe Y, Endoh H, Yoshida K,
Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T: Analysis of
epidermal growth factor receptor gene mutation in patients with
non-small cell lung cancer and acquired resistance to gefitinib.
Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luckman SP, Coxon FP, Ebetino FH, Russell
RGG and Rogers MJ: Heterocycle-containing bisphosphonates cause
apoptosis and inhibit bone resorption by preventing protein
prenylation: Evidence from structure-activity relationships in J774
macrophages. J Bone Miner Res. 13:1668–1678. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dunford JE, Thompson K, Coxon FP, Luckman
SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ:
Structure-activity relationships for inhibition of farnesyl
diphosphate synthase in vitro and inhibition of bone resorption in
vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther.
296:235–242. 2001.PubMed/NCBI
|
|
11
|
Di Salvatore M, Orlandi A, Bagalà C,
Quirino M, Cassano A, Astone A and Barone C: Anti-tumour and
anti-angiogenetic effects of zoledronic acid on human non-small
cell lung cancer cell line. Cell Prolif. 44:139–146. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morgan G and Lipton A: Antitumor effects
and anticancer applications of bisphosphonates. Semin Oncol.
37(Suppl 2): S30–S40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kijima T, Koga F, Fujii Y, Yoshida S,
Tatokoro M and Kihara K: Zoledronic acid sensitizes renal cell
carcinoma cells to radiation by downregulating STAT1. PLoS One.
8:e646152013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fukai J, Koizumi F and Nakao N: Enhanced
anti-tumor effect of zoledronic acid combined with temozolomide
against human malignant glioma cell expressing
O6-methylguanine DNA methyltransferase. PLoS One.
9:e1045382014. View Article : Google Scholar
|
|
15
|
Huang CY, Wang L, Feng CJ, Yu P and Wang
YS: Cooperation of bisphosphonates with tyrosine kinase inhibitors
in advanced non-small cell lung cancer with EGFR activation
mutation: A retrospective study. J Clin Oncol. 32:e190732014.
|
|
16
|
Chang JW, Hsieh JJ, Shen YC, Yeh KY, Wang
CH, Li YY and Hsu T: Bisphosphonate zoledronic acid enhances the
inhibitory effects of gefitinib on EGFR-mutated non-small cell lung
carcinoma cells. Cancer Lett. 278:17–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen W, Shen X, Xia X, Xu G, Ma T, Bai X
and Liang T: NSC 74859-mediated inhibition of STAT3 enhances the
anti-proliferative activity of cetuximab in hepatocellular
carcinoma. Liver Int. 32:70–77. 2012. View Article : Google Scholar
|
|
18
|
Wang M, Chen GY, Song HT, Hong X, Yang ZY
and Sui GJ: Significance of CXCR4, phosphorylated STAT3 and VEGF-A
expression in resected non-small cell lung cancer. Exp Ther Med.
2:517–522. 2011.PubMed/NCBI
|
|
19
|
Fromigue O, Lagneaux L and Body J-J:
Bisphosphonates induce breast cancer cell death in vitro. J Bone
Miner Res. 15:2211–2221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matsumoto S, Kimura S, Segawa H, Kuroda J,
Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T and Wada H: Efficacy
of the third-generation bisphosphonate, zoledronic acid alone and
combined with anti-cancer agents against small cell lung cancer
cell lines. Lung Cancer. 47:31–39. 2005. View Article : Google Scholar
|
|
21
|
Li YY, Chang JW, Chou WC, Liaw CC, Wang
HM, Huang JS, Wang CH and Yeh KY: Zoledronic acid is unable to
induce apoptosis, but slows tumor growth and prolongs survival for
non-small-cell lung cancers. Lung Cancer. 59:180–191. 2008.
View Article : Google Scholar
|
|
22
|
Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang
PY, Xu HX, Kong LQ, Wang L, Wu WZ and Tang ZY: Depletion of
tumor-associated macrophages enhances the effect of sorafenib in
metastatic liver cancer models by antimetastatic and antiangiogenic
effects. Clin Cancer Res. 16:3420–3430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Previdi S, Scolari F, Chilà R, Ricci F,
Abbadessa G and Broggini M: Combination of the c-Met inhibitor
tivantinib and zoledronic acid prevents tumor bone engraftment and
inhibits progression of established bone metastases in a breast
xenograft model. PLoS One. 8:e791012013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Beuselinck B, Wolter P, Karadimou A,
Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ,
Berkers J, et al: Concomitant oral tyrosine kinase inhibitors and
bisphosphonates in advanced renal cell carcinoma with bone
metastases. Br J Cancer. 107:1665–1671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keizman D, Ish-Shalom M, Pili R, Hammers
H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M,
Hayat H, et al: Bisphosphonates combined with sunitinib may improve
the response rate, progression free survival and overall survival
of patients with bone metastases from renal cell carcinoma. Eur J
Cancer. 48:1031–1037. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ling YH, Lin R and Perez-Soler R:
Erlotinib induces mitochondrial-mediated apoptosis in human H3255
non-small-cell lung cancer cells with epidermal growth factor
receptorL858R mutation through mitochondrial oxidative
phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol.
74:793–806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Okamoto K, Okamoto I, Okamoto W, Tanaka K,
Takezawa K, Kuwata K, Yamaguchi H, Nishio K and Nakagawa K: Role of
survivin in EGFR inhibitor-induced apoptosis in non-small cell lung
cancers positive for EGFR mutations. Cancer Res. 70:10402–10410.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gong YX, Somwar R, Politi K, Balak M,
Chmielecki J, Jiang X and Pao W: Induction of BIM is essential for
apoptosis triggered by EGFR kinase inhibitors in mutant
EGFR-dependent lung adenocarcinomas. PLoS Med. 4:e2942007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Senaratne SG, Pirianov G, Mansi JL, Arnett
TR and Colston KW: Bisphosphonates induce apoptosis in human breast
cancer cell lines. Br J Cancer. 82:1459–1468. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tassone P, Tagliaferri P, Viscomi C,
Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese
A, Boland CR, et al: Zoledronic acid induces antiproliferative and
apoptotic effects in human pancreatic cancer cells in vitro. Br J
Cancer. 88:1971–1978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu M, Yuan Y, Pan YY and Zhang Y:
Antitumor activity of combination treatment with gefitinib and
docetaxel in EGFR-TKI-sensitive, primary resistant and acquired
resistant human non-small cell lung cancer cells. Mol Med Rep.
9:2417–2422. 2014.PubMed/NCBI
|
|
32
|
Mu X, Zhang Y, Qu X, Hou K, Kang J, Hu X
and Liu Y: Ubiquitin ligase Cbl-b is involved in icotinib
(BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR
mutation-positive non-small cell lung cancer. BioMed Res Int.
2013:7263752013. View Article : Google Scholar
|
|
33
|
Li T, Ling YH, Goldman ID and Perez-Soler
R: Schedule-dependent cytotoxic synergism of pemetrexed and
erlotinib in human non-small cell lung cancer cells. Clin Cancer
Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li YY, Chang JW, Liu YC, Wang CH, Chang
HJ, Tsai MC, Su SP and Yeh KY: Zoledronic acid induces cell-cycle
prolongation in murine lung cancer cells by perturbing cyclin and
Ras expression. Anticancer Drugs. 22:89–98. 2011. View Article : Google Scholar
|
|
35
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wen Z, Zhong Z and Darnell JE Jr: Maximal
activation of transcription by Stat1 and Stat3 requires both
tyrosine and serine phosphorylation. Cell. 82:241–250. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kiper HD, Tezcanli Kaymaz B, Gokbulut AA,
Selvi N, Avci CB, Kosova B, Iskender G, Yandim MK, Gunduz C, Sahin
F, et al: STAT pathway in the regulation of zoledronic acid-induced
apoptosis in chronic myeloid leukemia cells. Biomed Pharmacother.
67:527–532. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reuben JS, Dinh L, Lee J, Stateson J,
Kamara H, Xiang L and Opperman LA: Bisphosphonates inhibit
phosphorylation of signal transducer and activator of transcription
3 and expression of suppressor of cytokine signaling 3:
Implications for their effects on innate immune function and
osteoclastogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 111:196–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koto K, Murata H, Kimura S, Sawai Y, Horie
N, Matsui T, Ryu K, Ashihara E, Maekawa T, Kubo T, et al:
Zoledronic acid significantly enhances radiation induced apoptosis
against human fibrosarcoma cells by inhibiting radioadaptive
signaling. Int J Oncol. 42:525–534. 2013.
|
|
41
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Robinson KW and Sandler AB: The role of
MET receptor tyrosine kinase in non-small cell lung cancer and
clinical development of targeted anti-MET agents. Oncologist.
18:115–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ringerike T, Blystad FD, Levy FO, Madshus
IH and Stang E: Cholesterol is important in control of EGF receptor
kinase activity but EGF receptors are not concentrated in caveolae.
J Cell Sci. 115:1331–1340. 2002.PubMed/NCBI
|
|
44
|
Mantha AJ, Hanson JEL, Goss G, Lagarde AE,
Lorimer IA and Dimitroulakos J: Targeting the mevalonate pathway
inhibits the function of the epidermal growth factor receptor. Clin
Cancer Res. 11:2398–2407. 2005. View Article : Google Scholar : PubMed/NCBI
|
